Last reviewed · How we verify
Erlotinib, escalating dose
At a glance
| Generic name | Erlotinib, escalating dose |
|---|---|
| Also known as | Tarceva |
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
- A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors (PHASE1)
- Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer (PHASE1)
- A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment (PHASE2)
- Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC (PHASE1)
- Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer (PHASE1)
- Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (PHASE1, PHASE2)
- Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Erlotinib, escalating dose CI brief — competitive landscape report
- Erlotinib, escalating dose updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI